Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Protara reported $161.9 million in cash, cash equivalents and investments, expected to fund planned operations into 2028, alongside progress across its late-stage pipeline. Interim data from the STARBORN-1 trial demonstrated an 83% clinical success rate for TARA-002 in Lymphatic Malformations, with a BLA submission planned for the second half of 2027.
Key figures
- Net loss
- $21.7 million
- Ga expenses
- $6.4 million
- Rd expenses
- $17.0 million
- Cash position
- $161.9 million
- Starborn 1 success rate
- 83%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.